ÂÜÀòÂÒÂ×

Mr. Rieflin joined the board in April 2016 as an independent board member bringing more than 20 years of industry experience. Most recently, he served as the Chief Executive Officer of NGM Bio. Prior to NGM Bio (NASDAQ: NGM), he was President of XenoPort, Inc. (NASDAQ: XNPT). Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel, and Secretary for Tularik Inc. (NASDAQ: TLRK), which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel, and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. In addition to RAPT Therapeutics and NGM Bio, he currently serves on the Board of Directors of Kallyope Inc. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business, and his J.D. from Stanford Law School.